Literature DB >> 15674362

Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.

W J M Mackus1, A P Kater, A Grummels, L M Evers, B Hooijbrink, M H H Kramer, J E Castro, T J Kipps, R A W van Lier, M H J van Oers, E Eldering.   

Abstract

We investigated the apoptosis gene expression profile of chronic lymphocytic leukemia (CLL) cells in relation to (1) normal peripheral and tonsillar B-cell subsets, (2) IgV(H) mutation status, and (3) effects of cytotoxic drugs. In accord with their noncycling, antiapoptotic status in vivo, CLL cells displayed high constitutive expression of Bcl-2 and Flip mRNA, while Survivin, Bid and Bik were absent. Paradoxically, along with these antiapoptotic genes CLL cells had high-level expression of proapoptotic BH3-only proteins Bmf and Noxa. Treatment of CLL cells with fludarabine induced only the proapoptotic genes Bax and Puma in a p53-dependent manner. Interestingly, the degree of Puma induction was more pronounced in cells with mutated IgVH genes. Thus, disturbed apoptosis in CLL is the net result of both protective and sensitizing aberrations. This delicate balance can be tipped via induction of Puma in a p53-dependent matter, the level of which may vary between groups of patients with a different tendency for disease progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674362     DOI: 10.1038/sj.leu.2403623

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  26 in total

Review 1.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 2.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

3.  Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

Authors:  Mercè de Frias; Daniel Iglesias-Serret; Ana M Cosialls; Llorenç Coll-Mulet; Antonio F Santidrián; Diana M González-Gironès; Esmeralda de la Banda; Gabriel Pons; Joan Gil
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

4.  Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.

Authors:  Manujendra N Saha; Hua Jiang; Hong Chang
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

5.  Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA.

Authors:  Erik Slinger; Felix M Wensveen; Jeroen E Guikema; Arnon P Kater; Eric Eldering
Journal:  Haematologica       Date:  2016-06-13       Impact factor: 9.941

6.  Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.

Authors:  Maria Baou; Susan L Kohlhaas; Michael Butterworth; Meike Vogler; David Dinsdale; Renata Walewska; Aneela Majid; Eric Eldering; Martin J S Dyer; Gerald M Cohen
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

7.  Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad.

Authors:  Anna Frenzel; Verena Labi; Waldemar Chmelewskij; Christian Ploner; Stephan Geley; Heidelinde Fiegl; Alexandar Tzankov; Andreas Villunger
Journal:  Blood       Date:  2009-12-03       Impact factor: 22.113

8.  BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent protein synthesis.

Authors:  F Grespi; C Soratroi; G Krumschnabel; B Sohm; C Ploner; S Geley; L Hengst; G Häcker; A Villunger
Journal:  Cell Death Differ       Date:  2010-08-13       Impact factor: 15.828

9.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

Authors:  Kensuke Kojima; Marina Konopleva; Teresa McQueen; Susan O'Brien; William Plunkett; Michael Andreeff
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

10.  Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.

Authors:  Sanjeev Kumar; Christopher S Bryant; Sreedhar Chamala; Aamer Qazi; Shelly Seward; Jagannath Pal; Christopher P Steffes; Donald W Weaver; Robert Morris; John M Malone; Masood A Shammas; Madhu Prasad; Ramesh B Batchu
Journal:  Mol Cancer       Date:  2009-04-22       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.